Rapid, Point-of-Care scFv-SERS Assay for Femtogram Level Detection of SARS-CoV-2 | Zendy

Delphine Antoine | Zendy; Moein Mohammadi | Zendy; Madison Vitt | Zendy; Julia Marie Dickie | Zendy; Sharmin Sultana Jyoti | Zendy; Maura A. Tilbury | Zendy; Patrick A. Johnson | Zendy; Karen Wawrousek | Zendy; J. Gerard Wall | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Rapid, Point-of-Care scFv-SERS Assay for Femtogram Level Detection of SARS-CoV-2

Author(s) -

Delphine Antoine,

Moein Mohammadi,

Madison Vitt,

Julia Marie Dickie,

Sharmin Sultana Jyoti,

Maura A. Tilbury,

Patrick A. Johnson,

Karen Wawrousek,

J. Gerard Wall

Publication year - 2022

Publication title -

acs sensors

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.055

H-Index - 57

ISSN - 2379-3694

DOI - 10.1021/acssensors.1c02664

Subject(s) - biopanning , coronavirus , immunoassay , virology , chemistry , covid-19 , recombinant dna , detection limit , virus , antibody , microbiology and biotechnology , peptide library , biology , chromatography , peptide sequence , biochemistry , medicine , infectious disease (medical specialty) , gene , immunology , disease , pathology

Rapid, sensitive, on-site identification of SARS-CoV-2 infections is an important tool in the control and management of COVID-19. We have developed a surface-enhanced Raman scattering (SERS) immunoassay for highly sensitive detection of SARS-CoV-2. Single-chain Fv (scFv) recombinant antibody fragments that bind the SARS-CoV-2 spike protein were isolated by biopanning a human scFv library. ScFvs were conjugated to magnetic nanoparticles and SERS nanotags, followed by immunocomplex formation and detection of the SARS-CoV-2 spike protein with a limit of detection of 257 fg/mL in 30 min in viral transport medium. The assay also detected B.1.1.7 ("alpha"), B.1.351 ("beta"), and B.1.617.2 ("delta") spike proteins, while no cross-reactivity was observed with the common human coronavirus HKU1 spike protein. Inactivated whole SARS-CoV-2 virus was detected at 4.1 × 10 4 genomes/mL, which was 10-100-fold lower than virus loads typical of infectious individuals. The assay exhibited higher sensitivity for SARS-CoV-2 than commercial lateral flow assays, was compatible with viral transport media and saliva, enabled rapid pivoting to detect new virus variants, and facilitated highly sensitive, point-of-care diagnosis of COVID-19 in clinical and public health settings.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research